Matches in Wikidata for { <http://www.wikidata.org/entity/Q92027269> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q92027269 description "article scientifique publié en 2020" @default.
- Q92027269 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92027269 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92027269 description "scientific article published on 17 April 2020" @default.
- Q92027269 description "wetenschappelijk artikel" @default.
- Q92027269 description "наукова стаття, опублікована 17 квітня 2020" @default.
- Q92027269 name "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 name "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 type Item @default.
- Q92027269 label "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 label "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 prefLabel "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 prefLabel "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 P1433 Q92027269-A6F1F130-2961-4337-B4DF-B25F141F5A43 @default.
- Q92027269 P1476 Q92027269-DEE48DD8-2B15-4752-8D41-EEAD74C0BE79 @default.
- Q92027269 P2093 Q92027269-1EE89573-21B8-403A-9641-A98CDB1DB39D @default.
- Q92027269 P2093 Q92027269-60EFBCB2-AA7B-4018-AC90-15155D3B5410 @default.
- Q92027269 P2093 Q92027269-68E00926-1A9E-44A4-990F-04B29050E553 @default.
- Q92027269 P2093 Q92027269-A516BA51-4BE2-4721-8063-83BEC050AAF6 @default.
- Q92027269 P31 Q92027269-740D1CFD-AB4F-4416-AB55-1A00804D2BDB @default.
- Q92027269 P356 Q92027269-06837203-08FD-4777-8529-5DF90ACFF867 @default.
- Q92027269 P577 Q92027269-4EF48FED-6E8C-4ADB-83AB-C48ECFBC35F2 @default.
- Q92027269 P698 Q92027269-B7410359-B833-4E11-B8E0-1322B300A949 @default.
- Q92027269 P921 Q92027269-1914B990-C233-4968-B6EF-1F15577BD55B @default.
- Q92027269 P921 Q92027269-1CEAB33C-B8D6-4D9F-B36A-4485E0B24F19 @default.
- Q92027269 P921 Q92027269-96631F86-947D-4F79-8B99-BD4CF23933C5 @default.
- Q92027269 P932 Q92027269-DBC86A4D-1870-45A1-B9D4-C92EDAA6C143 @default.
- Q92027269 P356 S40744-020-00204-9 @default.
- Q92027269 P698 32303994 @default.
- Q92027269 P1433 Q27727370 @default.
- Q92027269 P1476 "Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany" @default.
- Q92027269 P2093 "Gerd Rüdiger Burmester" @default.
- Q92027269 P2093 "Klaus Krüger" @default.
- Q92027269 P2093 "Matthias H Thomas" @default.
- Q92027269 P2093 "Siegfried Wassenberg" @default.
- Q92027269 P31 Q13442814 @default.
- Q92027269 P356 "10.1007/S40744-020-00204-9" @default.
- Q92027269 P577 "2020-04-17T00:00:00Z" @default.
- Q92027269 P698 "32303994" @default.
- Q92027269 P921 Q187255 @default.
- Q92027269 P921 Q511097 @default.
- Q92027269 P921 Q52849 @default.
- Q92027269 P932 "7211218" @default.